Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by Floridas2000on Aug 18, 2016 2:50pm
81 Views
Post# 25155417

RE:RE:RE:RE:RE:RE:Very informative article from director of Tribute

RE:RE:RE:RE:RE:RE:Very informative article from director of TributeMy opinion on your post Kuato is that it can hurt the value of the stock.  That someone reading it who is thinking of buying it might go, "this poster seems knowledgeable and he thinks management is bad.  I am not convinced that this is a good stock to buy in."  It CAN hurt shareholder value and I wouldn't make a statement like that unless I exited the position and I want to disturb shiit.  I have read some real good posts that exposed issues with a company and decided not to take the risk so does happen.

Next telling an insider who was there at all these key meetings is not going to go anywhere.  All he says is I know more than you know and he would be right.  I believe Tribute could've gotten a better deal in the merger but I'm not passing judgement until Yosprala is approved and sales figure in.  One great thing is the sales team is doing a wonderful job and if they do it to Yosprala with his confidence an acquisition is done this year then we'll be fine. 
<< Previous
Bullboard Posts
Next >>